If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  New Guidelines List Active Agents for Rare Sarcoma: Presented at NCCN By Ed Susman HOLLYWOOD, Fla -- March 15, 2010 -- Although definite clinical trial data are lacking, doctors inserted into guidelines possible treatments for rare soft-tissue sarcomas at the 15th Annual National Comprehensive Cancer Network (NCCN) Conference on Clinical Practice Guidelines and Quality Cancer Care. “This listing is based upon public literature and academic public presentations,” said George Demetri, MD, Center for Sarcoma and Bone Oncology at the Dana Farber Cancer Institute, Boston, Massachusetts. The listing includes all therapeutic agents approved for some indication by the US Food and Drug Administration. The list does not include any investigational agents, he said during his presentation on March 12. Some of the sarcomas -- such as perivascular epithelioid cell tumour, for example, are so rare that only a handful of cases are reported each year. He said that treatment with sirolimus appears to have some activity in this disease. He noted that most of the recommendations in the list involve low-level evidence of effectiveness -- they do not meet the highest criteria of controlled clinical trials. In some cases, clinical trials have been performed that establish treatment preferences, such as the use of imatinib in treatment of gastrointestinal stromal tumours. “The NCCN believes that the best management of any cancer patient is in a clinical trial; participation in a clinical trial is especially encouraged,” the guidelines state. Among the other disease states, and active agents used in those diseases are:
[Presentation title: NCCN Task Force Report: Gastrointestinal]
|
